Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAN-101
- Development stage
- Phase 2
- Lead developer
- AskBio
- Modality
- Gene Therapies
- Administration
- Intracoronary Infusion
01
Overview
NAN-101 (also known as AB-1002) is an investigational adeno-associated virus (AAV)-based gene therapy developed for the treatment of heart failure, specifically targeting patients with non-ischemic New York Heart Association (NYHA) Class III heart failure. The therapy is designed to deliver a gene encoding protein phosphatase inhibitor 1 (I-1c), which inhibits protein phosphatase 1 (PP1), a key enzyme implicated in the pathogenesis of heart failure. By increasing I-1c expression in cardiac tissue, NAN-101 aims to enhance cardiac contractility and improve overall heart function. The drug is administered as a single intracoronary infusion directly into the coronary arteries supplying the heart. Clinical trials have shown preliminary evidence of improved left ventricular ejection fraction and functional status in treated patients[1][3][5][9].
- Other names
- Carfostin
02
Targets
PP1 (Protein phosphatase 1)
Beyond the preview
Go deeper on NAN-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAN-101.